financetom
Business
financetom
/
Business
/
Visa Fiscal Q2 Non-GAAP EPS, Net Revenue Increase; Declares Dividend
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Visa Fiscal Q2 Non-GAAP EPS, Net Revenue Increase; Declares Dividend
Apr 23, 2024 1:33 PM

04:24 PM EDT, 04/23/2024 (MT Newswires) -- Visa (V) reported fiscal Q2 non-GAAP earnings late Tuesday of $2.51 per diluted share, up from $2.09 a year earlier.

Analysts polled by Capital IQ expected $2.43.

Net revenue for the quarter ended March 31 was $8.78 billion, up from $7.99 billion a year earlier.

Analysts surveyed by Capital IQ expected $8.62 billion.

The company's board declared a quarterly dividend of $0.52, payable on June 3 to holders of record on May 17.

Visa shares rose nearly 3% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alight Appoints Greg Giometti as Interim Chief Financial Officer
Alight Appoints Greg Giometti as Interim Chief Financial Officer
Mar 10, 2026
08:38 AM EST, 12/18/2025 (MT Newswires) -- Alight (ALIT) said Thursday it has appointed Greg Giometti as the company's interim chief financial officer, effective Jan. 9, 2026. Giometti succeeds Jeremy Heaton, who will depart Alight to pursue another opportunity, the company said. Giometti joined Alight in 2020 and currently serves as the company's senior vice president, head of financial planning...
Cybin to Transfer Listing to Nasdaq From NYSE American
Cybin to Transfer Listing to Nasdaq From NYSE American
Mar 10, 2026
08:39 AM EST, 12/18/2025 (MT Newswires) -- Cybin ( CYBN ) said Thursday that it will voluntarily transfer its listing to the Nasdaq Global Market from the NYSE American. Cybin ( CYBN ) said it expects its common shares will cease trading at the NYSE American at market close on Jan. 4 and start trading on Nasdaq at market open...
CAMP4 Therapeutics, GSK Collaborate to Develop RNA-Based Therapeutics for Neurodegenerative and Kidney Diseases
CAMP4 Therapeutics, GSK Collaborate to Develop RNA-Based Therapeutics for Neurodegenerative and Kidney Diseases
Mar 10, 2026
08:38 AM EST, 12/18/2025 (MT Newswires) -- CAMP4 Therapeutics ( CAMP ) said Thursday it has entered a research, collaboration and license agreement with GSK (GSK) to identify and develop antisense oligonucleotide drug candidates targeting neurodegenerative and kidney disease indications. Under the agreement, CAMP4 Therapeutics ( CAMP ) will receive upfront cash payment of $17.5 million and is eligible for...
ATS Receives Approval From TSX for Normal Course Issuer Bid
ATS Receives Approval From TSX for Normal Course Issuer Bid
Mar 10, 2026
08:39 AM EST, 12/18/2025 (MT Newswires) -- ATS (TSX and NYSE: ATS) on Thursday said that the Toronto Stock Exchange approved the company's notice of intention to make a normal course issuer bid (NCIB). Under the bid, the company will have the ability to buy back for cancellation up to a maximum of 8.2-million common shares, about 10% of the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved